<DOC>
	<DOCNO>NCT02040844</DOCNO>
	<brief_summary>The purpose study evaluate continue effectiveness safety Cat-PAD cat allergic subject five year start administration treatment . The study optional follow-up study phase III double-blind , placebo control , Cat-PAD study ; investigational product administer .</brief_summary>
	<brief_title>Phase III Cat-PAD Follow-on Study</brief_title>
	<detailed_description />
	<criteria>previously complete clinical study CP007 [ NCT01620762 ] start allergen therapy since complete CP007 Institutionalised due legal regulatory order</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>